BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 27699032)

  • 21. A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine.
    Lee KW; Kim BJ; Kim MJ; Han HS; Kim JW; Park YI; Park SR
    Cancer Res Treat; 2017 Jul; 49(3):706-716. PubMed ID: 27764906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer.
    Karthaus M; Hofheinz RD; Mineur L; Letocha H; Greil R; Thaler J; Fernebro E; Oliner KS; Boedigheimer M; Twomey B; Zhang Y; Demonty G; Köhne CH
    Br J Cancer; 2016 Nov; 115(10):1215-1222. PubMed ID: 27764839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of the Cost-Effectiveness of the SOX and COX Regimens in Patients with Unresectable Advanced and Recurrent Colorectal Cancer Using a Clinical Decision Analysis Approach].
    Nagase S; Iyoda T; Kanno H; Akase T; Arakawa I; Inoue T; Uetsuka Y
    Gan To Kagaku Ryoho; 2016 Oct; 43(10):1201-1205. PubMed ID: 27760938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
    Oza AM; Selle F; Davidenko I; Korach J; Mendiola C; Pautier P; Chmielowska E; Bamias A; DeCensi A; Zvirbule Z; González-Martín A; Hegg R; Joly F; Zamagni C; Gadducci A; Martin N; Robb S; Colombo N
    Int J Gynecol Cancer; 2017 Jan; 27(1):50-58. PubMed ID: 27749456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices.
    Lunacsek OE; Ravelo A; Coutinho AD; Hazard SJ; Green MR; Willey J; Eaddy M; Goertz HP
    Drugs Real World Outcomes; 2016 Sep; 3(3):333-343. PubMed ID: 27747837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Capecitabine and Oxaliplatin Before, During, and After Radiotherapy for High-Risk Rectal Cancer.
    Larsen FO; Markussen A; Jensen BV; Fromm AL; Vistisen KK; Parner VK; Linnemann D; Hansen RH; Johannesen HH; Schou JV
    Clin Colorectal Cancer; 2017 Jun; 16(2):e7-e14. PubMed ID: 27743742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials.
    Zhang ZC; Xu QN; Lin SL; Li XY
    PLoS One; 2016; 11(10):e0164663. PubMed ID: 27741288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer.
    Murphy AG; Casey R; Maguire A; Tosetto M; Butler CT; Conroy E; Reynolds AL; Sheahan K; O'Donoghue D; Gallagher WM; Fennelly D; Kennedy BN; O'Sullivan J
    Sci Rep; 2016 Oct; 6():34523. PubMed ID: 27739445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.
    Fujita H; Gomori A; Fujioka Y; Kataoka Y; Tanaka K; Hashimoto A; Suzuki T; Ito K; Haruma T; Yamamoto-Yokoi H; Harada N; Sakuragi M; Oda N; Matsuo K; Inada M; Yonekura K
    PLoS One; 2016; 11(10):e0164830. PubMed ID: 27736957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.
    Lam SW; Frederiks CN; van der Straaten T; Honkoop AH; Guchelaar HJ; Boven E
    Br J Cancer; 2016 Nov; 115(11):1335-1342. PubMed ID: 27736846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Nab-paclitaxel+gemcitabine therapy for adenosquamous carcinoma of the pancreas: an autopsy case].
    Kataoka K; Matsubara H; Urano F; Okamura S; Maeda M
    Nihon Shokakibyo Gakkai Zasshi; 2016; 113(10):1777-1784. PubMed ID: 27725467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination Chemotherapy of Mitomycin C and Methotrexate Was Effective on Metastatic Breast Cancer Resistant to Eribulin, Vinorelbine, and Bevacizumab after Anthracycline, Taxane, and Capecitabine.
    Tanabe M
    Case Rep Oncol; 2016; 9(2):422-426. PubMed ID: 27721762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.
    Nagaya T; Nakamura Y; Sato K; Harada T; Choyke PL; Hodge JW; Schlom J; Kobayashi H
    Oncotarget; 2017 Jan; 8(5):8807-8817. PubMed ID: 27716622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postoperative prophylactic hepatic arterial infusion chemotherapy for stage III colorectal cancer: a retrospective study.
    Wang Y; Sun XR; Feng WM; Bao Y; Zheng YY
    Onco Targets Ther; 2016; 9():5897-5902. PubMed ID: 27713643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma.
    Wang HY; Yao ZH; Tang H; Zhao Y; Zhang XS; Yao SN; Yang SJ; Liu YY
    Onco Targets Ther; 2016; 9():5663-5669. PubMed ID: 27713635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
    Meng S; Wu H; Wang J; Qiu Q
    Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression.
    Moiseyenko FV; Moiseyenko VM; Aleksakhina SN; Chubenko VA; Volkov NM; Kozyreva KS; Kramchaninov MM; Zhuravlev AS; Shelekhova KV; Ivantsov AO; Venina AR; Preobrazhenskaya EV; Mitiushkina NV; Iyevleva AG; Imyanitov EN
    Oncol Res Treat; 2016; 39(10):605-614. PubMed ID: 27710972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer.
    Xiao J; Xu X; Li X; Li Y; Liu G; Tan H; Shen H; Shi H; Cheng D
    Molecules; 2016 Sep; 21(10):. PubMed ID: 27706035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significant antitumor response of disseminated glioblastoma to bevacizumab resulting in long-term clinical remission in a patient with encephalocraniocutaneous lipomatosis: A case report.
    Fukaya R; Ozaki M; Kamamoto D; Tokuda Y; Kimura T; Fukuchi M; Fujii K
    Mol Clin Oncol; 2016 Oct; 5(4):417-421. PubMed ID: 27703677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.
    Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ
    Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.